# US 2021/0079020 A1 · Pyrrolobenzodiazepine-antibody conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079020 A1
- Document ID: US20210079020A1
- Status: Published application
- Kind: A1
- Application number: 16/484,313
- Filed: 2018-02-08
- Published: 2021-03-18
- Earliest claimed: 2017-02-08
- Assignees: Adc Therapeutics SA; MedImmune, LLC
- Applicants: Adc Therapeutics SA; Medimmune Limited
- Inventors: Patricius Hendrikus Cornelis VAN BERKEL
- Web page: https://patentgrep.com/patent/US20210079020A1

## CPC

- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/68035: {the drug being a pyrrolobenzodiazepine}
- A61K 47/6861: {the tumour determinant being from kidney or bladder cancer cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 2317/565: Complementarity determining region [CDR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody.

## Claims

### Claim at position 1

-138. (canceled)

### Claim 139

A conjugate of formula (I):
Ab-(DL)p (I)
wherein:
Ab is an antibody that binds to DLK1, KAAG1, or Mesothelin;
DL is
wherein:
X is selected from the group comprising: a single bond, —CH2— and —C2H4—;
n is from 1 to 8;
m is 0 or 1;
R7 is either methyl or phenyl;
when there is a double bond between C2 and C3, R2 is selected the group consisting of:
(ia) C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene;
(ib) C1-5 saturated aliphatic alkyl;
(ic) C3-6 saturated cycloalkyl;
wherein each of R21, R22 and R23 are independently selected from H, C1-3 saturated alkyl, C2-3 alkenyl, C2-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R2 group is no more than 5;
wherein one of R25a and R25b is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and
where R24 is selected from: H; C1-3 saturated alkyl; C2-3 alkenyl; C2-3 alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;
when there is a single bond between C2 and C3, R2 is
where R26a and R26b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R26a and R26b is H, the other is selected from nitrile and a C1-4 alkyl ester;
when there is a double bond between C2′ and C3′, R12 is selected the group consisting of:
(iia) C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene;
(iib) C1-5 saturated aliphatic alkyl;
(iic) C3-6 saturated cycloalkyl;
wherein each of R31, R32 and R33 are independently selected from H, C1-3 saturated alkyl, C2-3 alkenyl, C2-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R12 group is no more than 5;
wherein one of R35a and R35b is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and
where R24 is selected from: H; C1-3 saturated alkyl; C2-3 alkenyl; C2-3 alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;
when there is a single bond between C2′ and C3′, R12 is
where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester;
and p is from 1 to 8.

### Claim 140 (depends on 139)

The conjugate according to claim 139, wherein X is —CH2—.

### Claim 141 (depends on 139)

The conjugate according to claim 139, wherein n is 1 to 4.

### Claim 142 (depends on 141)

The conjugate according to claim 141, wherein n is 2.

### Claim 143 (depends on 139)

The conjugate according to claim 139, wherein there is a double bond between C2 and C3, and R2 is a C1-5 saturated aliphatic alkyl group.

### Claim 144 (depends on 143)

The conjugate according to claim 143, wherein R2 is methyl, ethyl or propyl.

### Claim 145 (depends on 139)

The conjugate according to claim 139, wherein there is a double bond between C2 and C3, and R2 is:
(a) phenyl, which bears one to three substituent groups, wherein the substituents may be selected from methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thiophenyl; or
(b) cyclopropyl; or
(c) a group of formula:
wherein the total number of carbon atoms in the R2 group is no more than 3; or
(d) the group:
or
(e) a group of formula:
wherein R24 is selected from H and methyl.

### Claim 146 (depends on 139)

The conjugate according to claim 139, wherein there is a single bond between C2 and C3, R2 is
and
(a) R26a and R26b are both H; or
(b) R26a and R26b are both methyl; or
(c) one of R26a and R26b is H, and the other is selected from C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted.

### Claim 147 (depends on 139)

The conjugate according to claim 139, wherein there is a double bond between C2′ and C3′, and R12 is a C1-5 saturated aliphatic alkyl group.

### Claim 148 (depends on 147)

The conjugate according to claim 147, wherein R12 is methyl, ethyl or propyl.

### Claim 149 (depends on 139)

The conjugate according to claim 139, wherein there is a double bond between C2′ and C3′, and R12 is:
(a) phenyl, which bears one to three substituent groups, wherein the substituents are selected from methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thiophenyl; or
(b) cyclopropyl; or
(c) a group of formula:
wherein the total number of carbon atoms in the R12 group is no more than 3; or
(d) the group:
or
(e) a group of formula:
wherein R34 is selected from H and methyl.

### Claim 150 (depends on 139)

The conjugate according to claim 139, wherein there is a single bond between C2′ and C3′, R12 is
and
(a) R36a and R36b are both H; or
(b) R36a and R36b are both methyl; or
(c) one of R36a and R36b is H, and the other is selected from C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted.

### Claim 151 (depends on 139)

The conjugate according to claim 139, wherein DL is:

### Claim 152 (depends on 139)

The conjugate according to claim 139, wherein, when the antibody binds to DLK1, the antibody comprises a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO.7, a VH CDR2 with the amino acid sequence of SEQ ID NO.6, and a VH CDR1 with the amino acid sequence of SEQ ID NO.5.

### Claim 153 (depends on 139)

The conjugate according to claim 139, wherein, when the antibody binds to DLK1, the antibody comprises a VH domain having the sequence of SEQ ID NO.1.

### Claim 154 (depends on 139)

The conjugate according to claim 139, wherein, when the antibody binds to DLK1, the antibody comprises a VL domain comprising a VL CDR3 with the amino acid sequence of SEQ ID NO.10, a VL CDR2 with the amino acid sequence of SEQ ID NO.9, and a VL CDR1 with the amino acid sequence of SEQ ID NO.8.

### Claim 155 (depends on 139)

The conjugate according to claim 139, wherein, when the antibody binds to DLK1, the antibody comprises a VL domain having the sequence of SEQ ID NO. 2.

### Claim 156 (depends on 139)

The conjugate according to claim 139, wherein, when the antibody binds to DLK1, the antibody comprises a heavy chain having the sequence of SEQ ID NO. 3, or a heavy chain having the sequence of SEQ ID NO. 11.

### Claim 157 (depends on 139)

The conjugate according to claim 139, wherein, when the antibody binds to DLK1, the antibody comprises a light chain having the sequence of SEQ ID NO. 4.

### Claim 158 (depends on 139)

A composition comprising a mixture of the antibody-drug conjugate compounds as defined in claim 139, wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is about 1 to about 4.

### Claim 159 (depends on 139)

A pharmaceutical composition comprising the conjugate of claim 139, and a pharmaceutically acceptable diluent, carrier, or excipient.

### Claim 160 (depends on 159)

The pharmaceutical composition of claim 159, further comprising a therapeutically effective amount of a chemotherapeutic agent.

### Claim 161 (depends on 160)

A method of treating cancer comprising administering to a patient the pharmaceutical composition of claim 160.

### Claim 162 (depends on 161)

The method of claim 161, wherein the patient is administered a chemotherapeutic agent in combination with the conjugate.
